project id: TCGA-PRAD; case submitter id: TCGA-G9-6354; source center: 23; state: released; a260 a280 ratio: 1.92; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.11; rna integrity number: 7.2; age at index: 55; days to birth: -20403; ethnicity: not hispanic or latino; gender: male; race: asian; vital status: Alive; year of birth: 1954; age at diagnosis: 20403; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic t: T2b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 2066.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2009; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; weight: 25.0; composition: Not Reported; days to sample procurement: 0; intermediate dimension: 0.1; longest dimension: 0.6; oct embedded: No; shortest dimension: 0.1; portion submitter id: TCGA-G9-6354-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 5.0; percent stromal cells: 25.0; percent tumor cells: 70.0; percent tumor nuclei: 80.0;